Norman and Olver Wittchen H-U, Carter RM, Pﬁsster H, et al. 2000. Disabilities and quality of life in pure and co-morbid generalised anxiety disorder and major depres- sion in a national survey. Int Clin Psychopharmacol, 15:319–28. Wittchen H-U, Nelson CB, Lachner G. 1998. Prevalence of mental disorders and psychosocial impairment in adolescents and young adults. Psychol Med, 28:109–26. Wohlreich MM, Mallinckrodt CH, Prakash A, et al. 2007. Duloxetine for the treatment of major depressive diosrder: safety and tolerability associated with dose escalation. Depress Anxiety, 24:41–52. Wong DT. 1998. Duloxetine (LY248686): an inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate. Exp Opin Investig Drugs, 7:1–9. Yonkers KA, Dyck IR, Warshaw M, et al. 2000. Factors predicit- ing the course of generalised anxiety disorder. Br J Psychiatry, 176:544–9. Zhang L, Chappell J, Gonzales CR, et al. 2007. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study. J Cardiovasc Pharmacol, 49:146–53. 1180 Neuropsychiatric Disease and Treatment 2008:4(6)